Skip to main content
S&P 5007,722.72+0.73%DOW51,176.96+0.49%NASDAQ27,190.86+1.19%BTC$84,501.00-0.42%ETH$2,668.21-1.39%GOLD$4,172.10-0.72%OIL$91.26-1.73%
Smart Investors Daily
SID Premium
BC

NASDAQ · BCAX

Bicara Therapeutics Inc. Common Stock

Healthcare · Biotechnology

$18.20

Down-$0.57 (-3.13%)

Updated Oct 3, 2026, 12:04 AM

SID Score

4.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.03B
P/E ratio
-10.02
Dividend yield
0.00%
52-week range
$13.70 – $30.99
Volume
698.05K
Avg. volume
676.71K

Price performance · BCAX

BCAX price history

1M range · 19 trading sessions · Daily adjusted prices

Prices through Oct 1, 2026

BCAX closed at $18.20 after 19 trading sessions, down 21.45% for the selected period.

Last close
$18.20
Period change
-21.45%
Period low
$18.20
Period high
$23.71
Daily close
View OHLC price history
BCAX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 1, 2026$18.61$19.23$18.12$18.20698.05K
Sep 30, 2026$18.71$18.95$18.385$18.61905.37K
Sep 29, 2026$18.88$19.39$18.51$18.56599.78K
Sep 28, 2026$19.21$19.26$18.59$18.80775.26K
Sep 25, 2026$19.86$19.89$19.17$19.21662.51K
Sep 24, 2026$20.43$20.84$19.33$19.781.37M
Sep 23, 2026$22.78$23.115$20.48$20.485954.77K
Sep 22, 2026$22.31$22.91$22.225$22.78622.17K
Sep 21, 2026$23.06$23.34$21.95$22.01315.35K
Sep 18, 2026$22.66$22.855$22.26$22.64934.23K
Sep 17, 2026$22.40$22.98$22.375$22.59491.97K
Sep 16, 2026$22.74$23.25$21.86$22.00798.33K
Sep 15, 2026$23.11$23.11$22.465$22.67706.49K
Sep 14, 2026$22.88$23.618$22.51$23.20426.35K
Sep 11, 2026$23.29$24.23$22.40$22.81471.46K
Sep 10, 2026$23.31$23.625$22.50$23.10644.78K
Sep 9, 2026$23.37$23.98$23.095$23.64550.21K
Sep 8, 2026$22.64$23.98$22.26$23.71709.97K
Sep 4, 2026$23.09$23.465$22.8462$23.17296.88K

Latest BCAX news

The latest Smart Investors Daily articles mentioning BCAX.

Stock researchCompany · Overview

BCAX research

Overview

Company profile and research snapshot.

Company profile

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$40.00
Implied upside
—
Analysts
—
BCAX recent ratings
DateFirmRatingTarget
Aug 19, 2026BMO CapitalOutperform—
Aug 12, 2026WedbushOutperform—
Aug 12, 2026Morgan StanleyOverweight—
Aug 12, 2026Goldman SachsNeutral—
Aug 12, 2026MizuhoNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awarded inducement grants on September 1, 2026 to two new employees as a material inducement to employment under Bicara’s 2026 Inducement Plan. The employees received, in the aggregate, non-qualified stock options to purchase 380,575 shares of Bicara’s common sto

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By